Table 1.
Demographics and clinical characteristics of patients
| Variable | N=19 (%)/[range] | P value |
|---|---|---|
| Gender | 0.326 | |
| Female | 12 (63.2) | |
| Male | 7 (36.8 | |
| Age, median | 58 [34–70] | |
| ECOG status | 0.617 | |
| 0 | 13 (68.4) | |
| 1 | 6 (31.6) | |
| Histopathology (biopsy) | 0.368 | |
| Adenocarcinoma | 18 (94.7) | |
| Squamous cell carcinoma | 1 (5.3) | |
| Genetic mutation | 0.282 | |
| EGFR | 16 (84.2) | |
| ALK | 2 (10.5) | |
| Nil | 1 (5.3) | |
| Clinical stage at diagnosis | 0.617 | |
| IIIA/IIIB | 4/2 (31.6) | |
| IVA/IVB | 12/1 (68.4) | |
| Preoperative staging after TKI | 0.154 | |
| IA | 2 (10.5) | |
| IIA/IIB | 2/2 (21.1) | |
| IIIA | 13 (68.4) | |
| ypStage | 0.352 | |
| IA/IB | 4/3 (36.8) | |
| IIB | 2 (10.5) | |
| IIIA/IIIB | 7/1 (42.1) | |
| IVA | 2 (10.5) | |
| Type of preoperative TKI | 0.091 | |
| Afatinib | 7 (36.8) | |
| Gefitinib | 6 (31.6) | |
| Erlotinib | 3 (15.8) | |
| Osimertinib | 1 (5.3) | |
| Alectinib | 1 (5.3) | |
| Crizotinib | 1 (5.3) | |
| Median duration of preoperative TKI, months | 5 [0.8–66] | 0.611 |
| Neoadjuvant | 2.5 [1.5-6] | |
| Treatment | 5.8 [0.8-66] | |
| Indication for preoperative TKI | 1.000 | |
| Neoadjuvant | 5 (26.3) | |
| Treatment | 14 (73.7) | |
| Indication for surgery | 0.123 | |
| Regressed disease | 17 (89.5) | |
| Regrowth disease | 2 (10.5) | |
| Duration of follow-up, median months | 22 [1–85] |
ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, TKI tyrosine kinase inhibitor